e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
New data on established treatments for COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Implications of under treatment of stable COPD (SAVING study)
Antonio Corrado (Firenze, Italy), Antonio Corrado, Andrea Rossi, On Behalf of SAVING/AIPO Study Group
Source:
International Congress 2015 – New data on established treatments for COPD
Session:
New data on established treatments for COPD
Session type:
Poster Discussion
Number:
1491
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Antonio Corrado (Firenze, Italy), Antonio Corrado, Andrea Rossi, On Behalf of SAVING/AIPO Study Group. Implications of under treatment of stable COPD (SAVING study). Eur Respir J 2015; 46: Suppl. 59, 1491
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Efficacy of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) on exacerbations and health status in GOLD Group D COPD patients: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
COPD: GOLD 2011 and implications for clinical practice
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
GOLD and phenotypes: The new Czech COPD guidelines
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Comparison of COPD patients with high and low symptoms from a real-world US survey
Source: International Congress 2015 – Non-inflammatory monitoring of airway diseases
Year: 2015
A self-treatment programme in patients with COPD: Effectiveness for the reduction of severe exacerbations
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO)
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
CAT in COPD phenotypes (POPE study)
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study
Source: International Congress 2016 – Novel insights into the treatment of COPD
Year: 2016
Outcomes in patients with COPD during a 3 year follow-up
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Clinical characteristics of patients with frequent COPD exacerbations in a Swiss multicenter COPD cohort study (TOPDOCS)
Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care
Year: 2016
Evaluation of the GOLD 2011 severity criteria across the COPD spectrum
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
What is the best biomarker of COPD stability?
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Outcomes of COPD exacerbations - a report from the ERS COPD audit in Austria
Source: Annual Congress 2013 –COPD: acute exacerbations and others
Year: 2013
RT protocol reduces AECOPD readmissions
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016
Validation of the COPD control concept: A UK pilot
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept